person · Reporting owner
DAMASIO JOSEPH LUIS JR
Disclosed activity across 2 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Chief Financial Officer | August 08, 2022 | August 09, 2022 |
| PRESSURE BIOSCIENCES INCPBIO · Entity 87205 | VP of FINANCE and CFO | December 19, 2018 | December 21, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harvard Apparatus Regenerative Technology, Inc.
Report date August 08, 2022 · Filed August 09, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.00 · Expires 2032-08-08 | Direct | 116,156 |
Reported balance
After 2022-08-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-08 · Grant · Acquired 116,156 · Balance 116,156 F1: Subject to continued employment through the applicable vesting dates, these shares vest in four equal annual increments on each anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Subject to continued employment through the applicable vesting dates, these shares vest in four equal annual increments on each anniversary of the grant date.
PRESSURE BIOSCIENCES INC
Report date December 19, 2018 · Filed December 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2028-07-18 | Direct | 0 |
Reported balance
After 2018-12-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-19 · Disposition to issuer · Disposed 3,334 · Balance 0 F1: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F3: 2015 Nonqualified Stock Option Plan. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2028-07-18 | Direct | 0 |
Reported balance
After 2018-12-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-12-19 · Disposition to issuer · Disposed 2,000 · Balance 0 F1: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F3: 2015 Nonqualified Stock Option Plan. |
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2028-07-18 | Direct | 0 |
Reported balance
After 2018-12-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2018-12-19 · Disposition to issuer · Disposed 3,334 · Balance 0 F1: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F3: 2015 Nonqualified Stock Option Plan. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2028-12-19 | Direct | 3,334 |
Reported balance
After 2018-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-12-19 · Grant · Acquired 3,334 · Balance 3,334 F1: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F2: Stock options vest 5/36th for the first month then 1/36th per month for the remaining months for a total of 36 months. F4: 2013 Equity Incentive Plan. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2028-12-19 | Direct | 5,334 |
Reported balance
After 2018-12-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2018-12-19 · Grant · Acquired 2,000 · Balance 5,334 F1: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F2: Stock options vest 5/36th for the first month then 1/36th per month for the remaining months for a total of 36 months. F4: 2013 Equity Incentive Plan. |
| Incentive Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2028-12-19 | Direct | 8,668 |
Reported balance
After 2018-12-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2018-12-19 · Grant · Acquired 3,334 · Balance 8,668 F1: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F2: Stock options vest 5/36th for the first month then 1/36th per month for the remaining months for a total of 36 months. F4: 2013 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028.
F2: Stock options vest 5/36th for the first month then 1/36th per month for the remaining months for a total of 36 months.
F3: 2015 Nonqualified Stock Option Plan.
F4: 2013 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 08, 2022 Filed Aug 9, 2022 18:06 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 116,156 | $0.00 Strike: $5.00 | $0.00 |
DisclosureSEC source: 0001104659-22-088076 · tm2222955-3_4seq1.xml · derivative · entry 1 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,156 Underlying: Common Stock, par value $0.01 per share · 116,156 shares Expires 2032-08-08 F1 · derivative.exercise_date: Subject to continued employment through the applicable vesting dates, these shares vest in four equal annual increments on each anniversary of the grant date. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 18:00 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | GrantIncentive Stock Option · Derivative | 3,334 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-017872 · ownership.xml · derivative · entry 6 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,668 Underlying: Common Stock · 3,334 shares Expires 2028-12-19 F1 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F2 · derivative.exercise_date: Stock options vest 5/36th for the first month then 1/36th per month for the remaining months for a total of 36 months. F4 · balance_after: 2013 Equity Incentive Plan. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 18:00 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | Disposition to issuerNon-Qualified Stock Option · Derivative | 3,334 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-017872 · ownership.xml · derivative · entry 5 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,334 shares Expires 2028-07-18 F1 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F3 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 18:00 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | GrantIncentive Stock Option · Derivative | 2,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-017872 · ownership.xml · derivative · entry 4 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Underlying: Common Stock · 2,000 shares Expires 2028-12-19 F1 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F2 · derivative.exercise_date: Stock options vest 5/36th for the first month then 1/36th per month for the remaining months for a total of 36 months. F4 · balance_after: 2013 Equity Incentive Plan. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 18:00 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | Disposition to issuerNon-Qualified Stock Option · Derivative | 2,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-017872 · ownership.xml · derivative · entry 3 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 F1 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F3 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 18:00 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | GrantIncentive Stock Option · Derivative | 3,334 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-017872 · ownership.xml · derivative · entry 2 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2028-12-19 F1 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F2 · derivative.exercise_date: Stock options vest 5/36th for the first month then 1/36th per month for the remaining months for a total of 36 months. F4 · balance_after: 2013 Equity Incentive Plan. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 18:00 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | Disposition to issuerNon-Qualified Stock Option · Derivative | 3,334 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-017872 · ownership.xml · derivative · entry 1 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,334 shares Expires 2028-07-18 F1 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F1 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option granted on July 18, 2018 and the grant of a replacement stock option dated December 19, 2018, which includes the same exercise price of $3.40 and a new expiration date of December 19, 2028. F3 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:23 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | GrantNon-Qualified Stock Option · Derivative | 3,334 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-010311 · ownership.xml · derivative · entry 7 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,668 Underlying: Common Stock · 3,334 shares Expires 2028-07-18 F2 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F4 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:23 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | Disposition to issuerNon-Qualified Stock Option · Derivative | 3,334 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001493152-18-010311 · ownership.xml · derivative · entry 6 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,334 shares Expires 2027-03-30 F2 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F4 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:23 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | GrantNon-Qualified Stock Option · Derivative | 2,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-010311 · ownership.xml · derivative · entry 5 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,334 Underlying: Common Stock · 2,000 shares Expires 2028-07-18 F2 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F4 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:23 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | Disposition to issuerNon-Qualified Stock Option · Derivative | 2,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001493152-18-010311 · ownership.xml · derivative · entry 4 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2027-03-17 F2 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F4 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:23 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | GrantNon-Qualified Stock Option · Derivative | 3,334 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-010311 · ownership.xml · derivative · entry 3 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,334 Underlying: Common Stock · 3,334 shares Expires 2028-07-18 F2 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F4 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:23 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | Disposition to issuerNon-Qualified Stock Option · Derivative | 3,334 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001493152-18-010311 · ownership.xml · derivative · entry 2 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,334 shares Expires 2026-01-01 F2 · date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F2 · derivative.exercise_date: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the old stock option and the grant of a replacement stock option, which includes a new exercise price of $3.40 and a new expiration date of July 18, 2028. F4 · balance_after: 2015 Nonqualified Stock Option Plan. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 17:23 UTC | PRESSURE BIOSCIENCES INC PBIO · Entity 87205 | GrantIncentive Stock Option · Derivative | 4,667 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001493152-18-010311 · ownership.xml · derivative · entry 1 DAMASIO JOSEPH LUIS JR · CIK 0001450080 · VP of FINANCE and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,667 Underlying: Common Stock · 4,667 shares Expires 2028-07-18 F1 · derivative.exercise_date: Incentive options vest 1/36th per month for 36 months, effective on the day of grant. F3 · balance_after: 2013 Equity Incentive Pan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.